Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Sep 11;25(4):630–637. doi: 10.1016/j.vaccine.2006.08.039

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — Induction of NT antibodies against SARS-CoV in rabbits pre-immunized with LC16m8. (A) Three rabbits (R13–15) were immunized with 10⁷ PFU of LC16m8 on day 0, and then immunized with 10⁷ PFU of RVV-S at 6 and 12 weeks. (B) Three rabbits (R4–6) were immunized with 10⁸ PFU of LC16m8 at 0 and 6 weeks, and then immunized with 10⁸ PFU of RVV-S at 12 and 18 weeks. Immunized rabbit sera were analyzed by in vitro NT assay against SARS-CoV (closed symbols) or vaccinia virus (open symbols). Each type of symbol indicates one and the same individual, and the schedule of immunization with RVV-S or LC16m8 is indicated by arrowheads. (C) Comparison of NT antibodies against SARS-CoV induced by RVV-S in VV-immunized or naïve rabbits. RVV-S (10⁷ or 10⁸ PFU) was injected into rabbits at 0 and 6 weeks in the presence (10⁷ PFU, R13–15; 10⁸ PFU, R4–6) or absence (10⁷ PFU, R10–12; 10⁸ PFU, R1–3) of pre-immunization with an equal titer of LC16m8. Immunized rabbit sera were analyzed by in vitro NT assay against SARS-CoV. ^**p < 0.01.